Prothena Corp PLC
Company Profile
Business description
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer’s disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Contact
77 Sir John Rogerson’s Quay
Block C
Grand Canal Docklands
Dublin 2D02 VK60
IRLT: +353 12362500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
163
Stocks News & Analysis
stocks
The best way to get rich and retire early
stocks
Investors overly negative on cheap ASX share
stocks
Overvalued US AI play reports earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,069.00 | 14.40 | -0.16% |
| CAC 40 | 8,103.85 | 17.22 | -0.21% |
| DAX 40 | 24,340.06 | 56.09 | 0.23% |
| Dow JONES (US) | 48,442.41 | 79.73 | 0.16% |
| FTSE 100 | 9,889.22 | 23.25 | 0.24% |
| HKSE | 25,818.93 | 44.79 | 0.17% |
| NASDAQ | 23,561.84 | 133.02 | 0.57% |
| Nikkei 225 | 50,364.65 | 48.22 | -0.10% |
| NZX 50 Index | 13,529.06 | 11.33 | 0.08% |
| S&P 500 | 6,909.79 | 31.30 | 0.46% |
| S&P/ASX 200 | 8,762.70 | 21.10 | -0.24% |
| SSE Composite Index | 3,942.21 | 22.23 | 0.57% |